CGC Joins Legislative Call to Delay Action on VALID Act

The CGC Board of Directors voted to sign a letter to Senators Patty Murray and Richard Burr organized by the Associate for Molecular Pathology (AMP) asking for delay of the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2022. Like many others, the CGC leadership is concerned that the VALID Act [S.2209/H.R.4128] would have significant consequences impacting delivery of laboratory-based healthcare, particularly in the development of new testing that is at the core of all we do. The letter was signed by over 70 other organizations and institutions. Click the URL link below to view this letter.

Search Clear Search Clear Category